Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.75 | N/A | -59.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.75 | N/A | -59.57% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions and their impact on performance. They highlighted initiatives aimed at enhancing efficiency but did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
There was no specific guidance provided for future performance.
This earnings report indicates that Neurocrine Biosciences faced significant challenges, resulting in a larger-than-expected loss per share. Despite the disappointing EPS, the stock rose by 1.96%, possibly due to investors' optimism about future operational improvements. The lack of revenue data and guidance leaves uncertainty about the company's near-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MATTEL INC